MiMedx Group came into this Q3 2026 report under a simple thesis in many investors minds. A low P/S multiple and growth forecasts were meant to offset real concerns about ongoing losses. Then the numbers hit. The stock slipped 2% to US$3.89 today, even as the company posted US$62.3m in net sales and turned adjusted EBITDA positive at US$2m.
The expectation gap sits squarely in profitability. Traders focused on another net loss of US$8.7m. The actual story is a sharp swing in earnings quality and margins that does not fully match the muted 1 day share move.
Love MiMedx Group's revenue base but concerned that recurring net losses could drag on your returns? Screen for companies that pair solid sales with consistent profitability using our list of solid balance sheet and fundamentals stocks (23 results).
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025): US$62.3m vs. US$113.7m (sharp year-on-year decline in quarterly sales)
-
Net Income/Loss (Q3 2026 vs. Q3 2025): loss of US$8.7m vs. profit of US$16.7m (swing from positive earnings to a quarterly loss)
-
Basic EPS (Q3 2026 vs. Q3 2025): loss of US$0.06 per share vs. earnings of US$0.11 per share (move back into loss per share t...